Compassionate grounds C Diff treatment interview

C Difficile is a gram positive, spore forming bacteria responsible for a debilitating gut infection, which infects and kills 500,000 and 30,000 North Americans respectively every year.

ImmuniMed Inc is a Winnipeg based clinical stage Biopharmaceutical company in phase 2 trials of its novel C Diff treatment. This interview records the personal experience of an individual suffering multiple recurrent C Diff infections.